Analysis of the Health Product Profile Directory - a new tool
                to inform priority-setting in global public health by Terry, R. F. et al.
RESEARCH Open Access
Analysis of the Health Product Profile
Directory — a new tool to inform priority-
setting in global public health
R. F. Terry1*, A. Plasència2,3 and J. C. Reeder1
Abstract
Background: The Health Product Profile Directory (HPPD) is an online database describing 8–10 key characteristics
(such as target population, measures of efficacy and dosage) of product profiles for medicines, vaccines, diagnostics
and other products that are intended to be accessed by populations in low- and middle-income countries. The
HPPD was developed by TDR on behalf of WHO and launched on 15 May 2019.
Methods: The contents of the HPPD were downloaded into an Excel™ spreadsheet via the open access interface
and analysed to identify the number of health product profiles by type, disease, year of publication, status, author
organization and safety information.
Results: The HPPD contains summaries of 215 health product profiles published between 2008 and May 2019, 117
(54%) of which provide a hyperlink to the detailed publication from which the summary was extracted, and the
remaining 98 provide an email contact for further information. A total of 55 target disease or health conditions are
covered, with 210 profiles describing a product with an infectious disease as the target. Only 5 product profiles in
the HPPD describe a product for a non-communicable disease. Four diseases account for 40% of product profiles in
the HPPD; these are tuberculosis (33 profiles, 15%), malaria (31 profiles, 14%), HIV (13 profiles, 6%) and Chagas (10
profiles, 5%).
Conclusion: The HPPD provides a new tool to inform priority-setting in global health — it includes all product
profiles authored by WHO (n = 51). There is a need to standardise nomenclature to more clearly distinguish
between strategic publications (describing research and development (R&D) priorities or preferred characteristics)
compared to target product profiles to guide a specific candidate product undergoing R&D. It is recommended
that all profiles published in the HPPD define more clearly what affordability means in the context where the
product is intended to be used and all profiles should include a statement of safety. Combining the analysis from
HPPD to a mapping of funds available for R&D and those products in the R&D pipeline would create a better
overview of global health priorities and how they are supported. Such analysis and increased transparency should
take us a step closer to measuring and improving coordination of efforts in global health R&D.
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Background
In this paper, we analyse the content of the new Health
Product Profile Directory (HPPD) developed by TDR
(the Special Programme for Research and Training in
Tropical Diseases) and assess the potential of HPPD as a
new tool to inform product priority-setting for global
health. The HPPD is a searchable database describing 8–
10 key characteristics (such as target population, mea-
sures of efficacy and dosage) of profiles for medicines,
vaccines, diagnostics and other products. The HPPD has
specific criteria to include only those product profiles
that describe health products intended to be accessed by
populations in low- and middle-income countries where
conventional research and development (R&D) market
incentives do not function for diseases sometimes de-
scribed as neglected diseases. The HPPD is a global pub-
lic good created by WHO as part of its efforts to
improve access to medicines and achieve universal
health coverage.
A product profile is a tool to plan and incentivise
R&D and can be used to frame the description of a
product for regulatory purposes [1]. The product profile
in different forms can serve different purposes. The Tar-
get Product Profile (TPP) provides strategic oversight to
optimise the development of existing product candidates
within the R&D pipeline. TPPs have primarily been used
by regulatory bodies and the pharmaceutical industry
since approximately 2005 [2], although we now see this
term also used in the not-for-profit space, for example,
by the Product Development Partnerships (PDP) [3].
Nevertheless, product profiles can also be written as
strategic documents describing an ideal or preferred set
of characteristics for a product that does not exist as a
way of setting a priority and guiding innovation in that
area. For WHO, these strategic profiles, often termed
Preferred Product Characteristics (PPC), aim to provide
a technical description of the characteristics (for ex-
ample, target population, dosage, efficacy) that the new
product will need to have to tackle that health priorities
effectively. In keeping with its mandate, WHO prefer-
ences reflect its desire to promote the development of
new products with high public health impact that are
suitable for use in low- and middle-income countries.
Using vaccine development as an example, a WHO
PPC document describes the indications, target groups,
possible immunisation strategies and features of the de-
sired clinical data related to safety and efficacy. These
preferences are related to the unmet public health need
in a priority disease area for which WHO encourages
vaccine development. A recent example includes vaccine
development for Ebola, where the commercial return on
a new product may not be sufficient to support the ne-
cessary R&D but the potential risk to public health is
great. The PPC does not describe minimally acceptable
criteria. Each PPC addresses early stage vaccine R&D,
generally at least 5–10 years from vaccine availability,
and they are reviewed and updated if necessary at least
every 5 years. PPC are not static exit criteria but are
structured in such a way so as to drive innovation for
early-stage products to address public health needs [4].
The issue of coordinating and financing R&D for prod-
ucts where markets are failing was the subject of a TDR
report in 2016. Following a request from the member
states of WHO, TDR undertook research that described
how a new global fund supporting R&D for neglected dis-
eases could be developed and managed. The subsequent
TDR report, Health Product Research and Development
Fund: a Proposal for Financing and Operation, developed
a new R&D modelling tool to predict the impact of seven
funding scenarios, ranging from an annual disbursement
of $1 million to $500 million, to improve global health
R&D funding and coordination [5, 6].
The 2016 report also highlighted the need for a global
mechanism to identify and communicate R&D priorities
and coordinate efforts to meet these. In the consulta-
tions undertaken for that report, product profiles were
identified as a tool that was becoming more widely used
by WHO, industry, the PDPs and funding agencies to
manage their R&D portfolios. The report concluded
that, if these product profiles could be summarised in a
standard template and brought together in a database
directory, this would improve access to information at a
global level on health product R&D. The more precise
description of public health needs contained in a prod-
uct profile would strengthen the efforts to develop new
health products where conventional markets were ab-
sent, for example, the poverty-related neglected diseases,
emerging pandemics or novel antibiotics. In addition, a
directory would enable a high-level analysis of global
health priorities, identify where there are gaps, and in-
form a discussion on what norms and standards are
need for subsequent product profile development.
Subsequently, TDR undertook a series of further con-
sultations with WHO staff and external stakeholders en-
gaged in global health product R&D (as listed in
Annex 2 of the 2016 TDR Report [5]) to develop this
online resource. Stakeholders were requested to provide
a link to a published product profile or to provide the
meta-data if there was no public document. The infor-
mation was collated and transposed to a standard tem-
plate summary or meta-data captured in a HPPD record
(Table 1).
The criteria for inclusion of a product profile in the
HPPD are (1) product profiles with a focus on addressing
health issues in low- and middle-income countries for
which there is no market or limited incentive for R&D; (2)
health product profiles covering pharmaceuticals/thera-
peutics, biologics, vaccines, diagnostics, medical devices/
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equipment; (3) all product profiles prioritized for global
action by WHO and its technical departments (these were
marked as authored by WHO); and (4) all product profiles
authored by other UN agencies, PDPs, commercial com-
panies and other organisations that share the same inclu-
sion criteria listed above (these are marked as non-WHO
profiles).
The first publication of HPPD was by design not
intended to provide a comprehensive analysis of all
health products in the pipeline.
The data were collated in a Microsoft Excel™
spreadsheet used to populate a web-based database
on the TDR website using Sitefinity™ software. The
HPPD was launched on 15 May 2019 [7, 8]. This
database includes a form to submit a new product
profile online given that one of the key aims of HPPD
is to provide up-to-date information. Users are
strongly encouraged to read the Frequently Asked
Questions document on this site before using the
HPPD or submitting a new profile [9].
Methods
The HPPD was accessed on 31 May 2019. An output of
the whole content of the HPPD was generated by using
the search function with no specific search values se-
lected. The HPPD creates a .CSV file, which was down-
loaded and saved into Microsoft Excel™ 2016. The Excel
file was then formatted and filters were added to enable
an analysis of the number of health products by type,
disease, year of publication, status, author organization
and safety information. Twenty profiles published be-
tween 2008 and 2013 were given an ‘Archive’ status as
internal best practice at WHO recommends that profiles
older than 5 years should be updated if they are to be
relevant in guiding R&D. The analysis presented here in-
cludes all 215 records comprising both Archive and Ac-
tive profiles.
Results
On 31 May 2019, the HPPD contained summaries of
215 health product profiles dating from 2008 through to
Table 1 Description of the health product profile characteristics contained in the Health Product Profile Directory (please note, not
all characteristics apply to all profiles)
Profile characteristic Example descriptions
Document title A description of the health product profile, including product type, target disease and/or health condition for a target
population or geographic location
Author The lead organisation that developed and published the health profile. When a profile was published in a journal, the main
institutional affiliation of the corresponding author was chosen
WHO A check-box to enable quick separation of WHO-authored health product profiles from those authored by others
Diseases One or more diseases and/or health conditions (e.g. reproductive health) targeted by the product
Product type Short-description of the product type: diagnostic, drug, vaccine, digital health, drug regimen, injectable/implant, not defined.
As the directory content grows, these definitions will expand
Year published The year the profile document was published
Status Active: the profile is still considered relevant
Archive: the profile is no longer relevant. In the Health Product Profile Directory, profiles older than 5 years from the current
date are considered archive
Indication The purpose of the product, e.g. to provide immunisation against a given disease or to identify the presence of a given
bacteria in drinking water
Intended use Primarily used for diagnostics to separate triage, screening and more precise diagnosis
Target population Age group or other specific subpopulation groups
Sample type and
volume
Primarily for diagnostics describing the medium that is tested, e.g. blood, stool, saliva, drinking water
Use setting Who would use the product and under what conditions, infrastructure requirements, e.g. trained nurse in a low-resource
setting, primary healthcare facility, no cold chain, shelf life
Performance Describes for diagnostics: specificity, sensitivity, reproducibility, robustness, time to result, nature of result, qualitative or
quantitative
Efficacy For drugs and drug regimens: the clinical characteristics, dosing, pharmaco-dynamics, rate of onset of action, interaction with
other therapeutics, etc.
For vaccines: expected efficacy, duration, reversibility, strain coverage, interaction with other vaccines, etc.
Safety For drugs, drug regimens and vaccines: clinical safety and tolerability, safety monitoring requirements, contra-indications and
relation to specific population types, e.g. infants, pregnant women, during breast-feeding
Comments Additional comments not able to be categorized above
Document url Ideally, an archive providing a permanent url where the full document is published openly on line
Contact email A contact email for further information
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May 2019. Of these, 117 (54%) provide a hyperlink to
the detailed publication from which the summary was
extracted, with the remaining 98 providing an email con-
tact for further information. Of the 117 with a published
document, 63 published the profile on the website of the
authoring organization, 31 were published in an online
academic journal and 23 were published in the digital re-
pository of WHO, called IRIS, with a link to the relevant
WHO webpage [10]. Publishing a product profile in a
journal or a digital repository should be encouraged as it
provides an archive-quality, permanent url reference for
the publication. Publications on websites are at risk of
the link breaking when webpages are updated and are
unreliable as references for documents of this nature.
All the profiles could be categorised as strategic docu-
ments in that they describe an ideal or preferred set of
characteristics. None of the documents provide any link
to a specific candidate that is undergoing R&D. There is
a wide variation of terms used to describe the profiles
with the term ‘Target Product Profile’, or a variation of
that phrase, used in 52 of the profiles. The HPPD con-
tains links to 10 WHO profiles for vaccines that are enti-
tled ‘Preferred Product Characteristics’ and the Bill and
Melinda Gates Foundation has 12 profiles that describe
an intervention as Target Product Profile. Both the PPC
and intervention TPPs are more explicit in describing
their purpose as strategic. However, due to the absence
of standard nomenclature, it is not reliable to infer the
purpose of a document in the HPPD from the title.
Similarly, it should be noted that, in the analysis pre-
sented here, each record was given equal weight and no
assessment to distinguish between the profiles with
respect to quality was made. For example, of the 129
profiles that describe a drug or vaccine, 58 (45%) of
these contain no reference to safety requirements. As
the HPPD is the first resource of its kind, the increased
visibility and ease of comparing profiles across categories
should act as a driver to improve standards and quality
over time.
In addition to the typical health product profiles for
diagnostics, drugs, vaccines and drug regimens, the
HPPD also contains other product profiles, including
seven profiles describing software to manage tubercu-
losis (TB) patient data, products for injectable or implant
contraception, and other profiles describing contracep-
tive methods for a target population where the specific
product type was undefined.
Fifty-five target disease or health conditions were cov-
ered by the 215 health product profiles, with 210 profiles
describing a product with an infectious disease as the
target (Fig. 1). Only five product profiles or less than 2%
of the profiles in the HPPD describe a product for a
non-communicable disease (NCD) (one vaccine for
breast cancer and four contraception technologies). The
top four diseases accounting for 40% of product profiles
in the HPPD were TB, malaria, HIV and Chagas
(Table 2).
All of the emerging diseases with potential to cause
pandemics identified by WHO in the R&D Blueprint are
covered by one to three product profiles describing diag-
nostics, drugs and vaccines [11]. By comparison, many
of the neglected tropical diseases have limited represen-
tation in the profiles, with many only having one or two
profiles.
Fig. 1 Number of health product profiles by disease (May 2019, n = 215)
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Of the 215 profiles, 16 (7%) are authored by for-profit
companies, with the remaining 199 being authored by
funding/advocacy agencies (95, 44%), WHO (includes
partnerships with UNICEF and the Global Antibiotic Re-
search and Development Partnership; 51, 24%), PDPs
(34, 16%), and public institutes and universities (17, 8%)
(Fig. 2). The top five organizations that reported product
profiles are shown below (Table 3).
The distribution of profiles is heavily weighted to
those agencies in the not-for-profit sector. This is to be
expected and reflects the inclusion criteria for the
HPPD, with its focus on global health where markets are
limited. Additionally, there might be a greater reluctance
to share specific product profile information in a TPP by
a commercial entity if that would compromise intellec-
tual property protection. However, now the HPPD is
launched, this concern may reduce when users can as-
sess for themselves that the summary information can
be presented in a way that would highlight what is in a
pipeline but not require them to reveal commercially
sensitive information.
Finally, an analysis of those profiles authored by WHO
are presented (Fig. 3). This demonstrates the potential of
the HPPD to undertake a high-level analysis of the port-
folio for an organisation. For WHO, the analysis
presented here represents all the known profiles that
have been published at the time of publication. The dis-
ease profile reflects the global analysis with a strong em-
phasis on infectious diseases and no profiles in the NCD
area.
Discussion
It is important to note that the profiles reported here are
those that are available in the public domain or have been
disclosed by a contact at the authoring institution. There
are many more products in the pipeline for which product
profiles, and more specifically TPPs, might exist. An ana-
lysis of the product pipeline for HIV, TB, malaria and the
neglected tropical diseases undertaken in 2017 reports a
total of 685 product candidates [12]. Therefore, the con-
tent of the HPPD, which has 210 profiles covering the
same diseases, suggests that coverage might be as low as
31% of what could be available. However, as we have
noted, all the profiles here could be considered strategic
documents and do not provide references that relate to
specific products in the pipeline. Therefore, this low
coverage could be the result of comparing two different
phases of the innovation cycle with the HPPD providing
upstream guidance and product pipeline analysis measur-
ing actual R&D activity. Moving forwards, we would want
Table 2 The four diseases with the highest number of product profiles in the Health Product Profile Directory (May 2019)
Tuberculosis 33 profiles (15%) Diagnostic (12), Drug (5), Vaccine (5), Digital Health (7),
Drug Regimen (4)
Malaria 31 profiles (14%) Diagnostic (9), Drug (16), Vaccine (6)
HIV 13 profiles (6%) Diagnostic (4), Drug (4), Vaccine (4), Injectable/implant (1)
Chagas 10 profiles (5%) Diagnostic (6), Drug (4)
Fig. 2 Product profiles by organisation author (May 2019, n = 215)
Terry et al. Health Research Policy and Systems           (2019) 17:97 Page 5 of 9
to be able to track the impact of a strategic product profile
on R&D activity, particularly those profiles authored by
WHO, to assess if they are meeting their stated aim of
stimulating innovation in areas of public health need. For
example, the WHO R&D Blueprint for emerging pan-
demic diseases has led to the creation of detailed product
profiles in diagnostics and vaccines. The creation of these
profiles, with a relatively standardized format, have been
adopted as the research priorities for the Coalition for Epi-
demic Preparedness Innovations (CEPI), which has subse-
quently provided $350 million in R&D funding [13]. Thus,
in time, it should be possible to trace the degree to which
these strategic profiles have stimulated and shaped R&D
funding. For the neglected tropical diseases with less
coverage in the HPPD, the indication is that more work is
needed to create a similar set of precise health product
profiles to better communicate product R&D priorities in
this area.
For NCDs, medical devices and reproductive health,
the number of profiles in the HPPD is below 2%. Thus,
if product profiles are to become the norm for describ-
ing product R&D priorities, then much more develop-
ment in needed in these disease areas.
A key consideration for inclusion of a health product
profile in the HPPD is that it describes a product for
which there is a limited market to provide the incentive
for traditional R&D. This means that access and afford-
ability should be embedded within a product profile and
particularly in any prospective profile describing Pre-
ferred Product Characteristics. In this sample, we were
able to observe some of the elements that relate to ac-
cess, such as target population, indication and intended
use in a low-resource setting but stating a specific price
point for the final product is absent from most product
profiles in this sample. Ten diagnostic profiles authored
by WHO include information on a minimal and optimal
target price per test, these target price points range from
$1–5 (excluding the cost of a device or reader). Whilst
recognising the complexities, stating a maximum price
for a product to ensure affordability in the target
Table 3 The top five organizations reporting product profiles in the Health Product Profile Directory (May 2019)
Global Health Innovative Technology Fund 62 profiles Diagnostics (18), Drug (26), Vaccine (18)
World Health Organization
(incl. Partnerships with UNICEF and Global Antibiotic
Research and Development Partnership)
51 profiles Diagnostics (17), Drug (3) Vaccine (21),
Digital Health (7), Drug Regimen (3)
Bill and Melinda Gates Foundation 24 profiles Drugs (4), Vaccine (13) Drug Regimen (1),
Injectable/implant (3), Not Defined (3)
Serum Institute 12 profiles Vaccines (12)
Drugs for Neglected Diseases Initiative 10 profiles Drugs (8), Vaccine (2)
Fig. 3 Product profiles authored by WHO, includes partnerships with UNICEF, Global Antibiotic Research and Development Partnership (May
2019, n = 215)
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countries should be an important consideration in all
product profiles aimed at use in low- and middle-
income countries. For example, the Meningitis Vaccine
Project identified affordability as a key guiding principle
when it developed the product development plan for a
new meningococcal vaccine in 2002. Following input
from public health leaders in the African countries
where the vaccine was needed, the target for the max-
imum cost per dose for the new vaccine was set at no
more than $0.50. Setting this price target early is cited as
one of the major contributing factors that subsequently
guided the research, development, uptake and use of this
vaccine (MenAfriVac) [14].
The variation of formats and detail in the product pro-
files and the widespread use of TPP to describe the types
of product profile with varying objectives means that,
without the standardisation provided by HPPD, it would
not be possible for any analysis or comparison to take
place. The HPPD provides that opportunity for the first
time in an online resource. While broad analysis can re-
veal significant gaps, for example, the lack of coverage of
the NCDs, more work needs to be done to develop stan-
dards if the use of product profiles is to become the
norm in describing priorities in global health product
R&D.
If product profiles are to drive innovation in the fu-
ture, then an ideal scenario can be imagined. Priorities
for global health R&D would be identified following an
evaluation of products in the current health system. By
incorporating input from a wide range of stakeholders,
including end users and patients, a consensus document
or roadmap would set out the value proposition. The
importance of gaining input from end-users is again
highlighted by the Meningitis Vaccine Project as it was
the feedback from the officials in the target Africa coun-
tries that made it clear that, unless the final vaccine cost
less than $0.50 a dose, they could not afford to use it
[14]. This roadmap would describe the public health
need and how a product of a certain type would best ad-
dress that need.
The technical specification describing these preferred
characteristics would be published in a PPC document.
In global health, a WHO-PPC should represent the high-
est level of global consensus. The PPC would describe
an ideal and set a measure or benchmark against which
new products could be assessed. Following publication
of a PPC, we would want to see this stimulate innovation
as evidenced by several TPP candidates entering the
pipeline (Fig. 4) [15].
Conclusion
The HPPD clearly demonstrates its potential to meet
many of the aims it was designed for. It brings together
health profiles (documents that describe PPCs and
TPPs) in a searchable database. The profiles are written
to describe priority health products (drugs, diagnostics,
vaccines and other devices) that are essential to tackle
pressing health needs with a focus on populations in
low- and middle-income countries. Currently, these doc-
uments are found in varied formats scattered across
Fig. 4 The role of health product profiles in shaping research and development (adapted from [15])
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webpages, in repositories or published in journals. Stan-
dardising the documents to a template and including
them in a free-to-access directory has enabled compari-
son and analysis across the profiles and the disease area
they target. As awareness of the HPPD grows, this
should increase access to the profiles and therefore their
impact. It is important to note the HPPD only published
a summary of the original document. If a reader wishes
to understand in more detail how a profile was devel-
oped and, for example, who was consulted during that
development, then they should always read the original
document.
The information contained in the HPPD should inform
any discussion of R&D priorities in global health, particularly
the need to include considerations of access, such as price,
at an early stage in the innovation cycle. All the current pro-
files authored by WHO are indexed and clearly labelled,
which will enable all interested stakeholders to identify and
access these documents. These documents aim to provide a
global consensus to guide and coordinate global health R&D
efforts, particularly where there is market failure. The HPPD
therefore addresses what has been termed a public health
failure by industry, i.e. the absence of clear, technical docu-
ments describing, in specific details, what characteristics a
new health product should have if it is to be effective in
tackling a disease in low-resource settings.
The HPPD is easy to navigate and this enables a user
to identify where a profile exists and, in most cases, find
more detailed information on that product profile. The
resource is open access, so all the data can be readily
downloaded into Excel for further analysis.
The analysis presented here highlights the need to de-
velop and agree standards in the production of health
product profiles, particularly if the use of strategic pro-
files is to become a norm for WHO-authored PPCs, with
their objective to describe global health R&D priorities.
In particular, it is recommended that all PPC profiles
should include statements that define the value propos-
ition more precisely. Whilst it may prove difficult to de-
fine exact price points that apply for all products in all
countries and for all populations/subpopulations, more
work needs to done to define what ‘affordability’ means.
All profiles should also include a statement regarding
safety. The authors are aware that WHO is developing
guidance for the development of WHO-authored pro-
files. These issues could be further addressed by a mod-
eration process requiring these fields to be completed as
a mandatory part of submission to the HPPD.
The utility of the HPPD will grow as more content is
ingested and this improvement in transparency should
enable us to track resource flows to those identified pri-
orities. In time, this should lead to a greater coordin-
ation of the resources we have available to tackle
pressing global public health needs.
Combining the analysis from HPPD to a mapping of
funds available for R&D, for example, as measured by
the annual G-FINDER survey for neglected diseases, and
products in the R&D pipeline as published by the WHO
Global Observatory on Health R&D, would create a bet-
ter overview of global health priorities and how they are
supported [16, 17]. This is the subject of ongoing work
by TDR with its partners Duke University and Policy
Cures Research due for publication later in 2019. Such
analysis and increased transparency should take us a
step closer to measuring and improving coordination of
efforts in global health R&D.
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